# Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

> **NCT03296553** · PHASE2 · COMPLETED · sponsor: **National Institute of Cancerología** · enrollment: 40 (actual)

## Conditions studied

- Kaposi Sarcoma
- Human Immunodeficiency Virus
- Immune Reconstitution Syndrome

## Interventions

- **DRUG:** Valganciclovir
- **DRUG:** Antiretroviral Combinations

## Key facts

- **NCT ID:** NCT03296553
- **Lead sponsor:** National Institute of Cancerología
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-01
- **Primary completion:** 2019-08-26
- **Final completion:** 2019-08-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03296553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03296553, "Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03296553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*